Newsroom

ProTom International Introduces Radiance 330-C

Woburn, Mass., September 27, 2024 - ProTom International, a leading provider of compact proton therapy technology that is transforming cancer treatment, is pleased to introduce its new proton therapy system, the Radiance 330-C Proton Therapy SystemTM. 

This new compact, fixed beam room configuration is a modular and economically viable proton therapy solution, enabling healthcare providers to develop single or multiple-room capabilities within or adjacent to an existing radiation oncology department. When integrated with Leo Cancer Care’s upright patient positioning and imaging system, Radiance 330-C will extend the offering of gantry-less proton therapy without sacrificing treatment capability to the industry, while reducing costs and increasing the flexibility of proton therapy centers. 

The system features Fidelity™ pencil beam scanning technology offering superior dose sculpting, an upright patient positioning system and diagnostic quality CT at the treatment isocenter which will enable real-time adaptive therapy. The stationary beam delivery system improves reliability, beam parameters, and accuracy while reducing maintenance costs. Additionally, it includes a compact synchrotron particle accelerator that delivers a clinical treatment energy range from 70 MeV to 250 MeV with a capacity of up to 330 MeV for future deployment of proton imaging.

ProTom International has addressed the high cost and large size constraints of proton therapy with the Radiance 330-C Proton Therapy System. The small footprint and modular design allow for the Radiance 330-C to be installed in purpose-built or existing facilities. The system is compact, flexible, and economically viable, allowing healthcare providers to develop single fixed beam capacity inside existing Linac vaults, making proton therapy an extension of radiation oncology. 

It offers several configurations, from single-room to multi-room setups, which can be arranged in various configurations to fit any real estate constraints. The largest equipment component requires no hatch, special crane, transport, or reinforced roadways and can be easily moved through typical freight or staff entrances. This simpler project with lower construction and equipment costs translates to faster time-to-market and quicker access for patients in need.

Paul Tso, CEO of ProTom comments: “ProTom is thrilled to introduce Radiance 330-C to the world. With Leo's Upright Positioning and imaging System, Radiance 330-C becomes even more accessible to those who need it but are constrained by space and resources. As ProTom promised, we are dedicated to providing healthcare providers with a modular, compact, and economically viable proton therapy solution. With this new compact proton therapy system, we can better achieve our goal.”

Stephen Towe, CEO of Leo Cancer Care shares similar sentiments: “Our mission has always been to bring Proton Therapy to as many people as possible. Making our solution available in as many configurations as possible is an important step to achieve this. This partnership with ProTom International signifies the industry’s willingness to innovate and breakdown existing barriers to better care.”

About ProTom

ProTom International is a leading device manufacturer of proton therapy technology. We are steadfast in our mission to transform cancer treatment by expanding the accessibility of proton therapy and by developing proton tomography technology.

Combined with the fast return on investment and the precision of pencil beam scanning and the power of integrated imaging, ProTom’s Radiance 330-C proton therapy system is the choice for future proton therapy technology.

For more information, please visit: https://www.protominternational.com

Contact us: https://protominternational.com/contact

Press contact: info@protominternational.com

Find us on Twitter, Facebook and LinkedIn

*The Radiance 330-C Proton Therapy System is not yet available for clinical use.